SNNA News and Press, Sienna Biopharmaceuticals Inc. From 03/14/19

WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results for the fourth quarter and full year of 2018. “We are pleased to report...

WESTLAKE VILLAGE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to prese...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Gainers:  Kandi Technologies Group (NASDAQ: KNDI ) +47% . LeMaitre Vascular (NASDAQ: LMAT ) +28% . AzurRx BioPharma (NASDAQ: AZRX ) +29% . Blink Charging (NASDAQ: BLNK ) +21% . Carrols Restaurant Group (NASDAQ: TAST ) +17% . OneSpan (NASDAQ: OSPN ) +17% . Garmin (NASDAQ: GRMN ) ...

Sienna Biopharmaceuticals (NASDAQ: SNNA ) prices its public offering of 8M common stock at a price of $2.50/share, for expected gross proceeds of $20M. More news on: Sienna Biopharmaceuticals, Healthcare stocks news, Stocks on the move, Read more ...

Aceto (NASDAQ: ACET ) -69%  on announcing proposed sale of its chemicals business assets. More news on: Aceto Corporation, Sienna Biopharmaceuticals, Owens & Minor Inc., Stocks on the move, Read more ...

WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $2.50 per...

Gainers: LNTH   +10.1% . CDNS   +6.6% . DVN   +6.6% . FIVN   +5.6% . NVTA   +4.9% . More news on: Lannett Company, Inc, Lantheus Holdings, Cadence Design Systems, Inc., Stocks on the move, , Read more ...

WESTLAKE VILLAGE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a proposed underwritten public offering of its common stock. All shares of common stock to be sold in ...

CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / The tech stock market will continue to be successful if, and only if, companies in the sector continue to invest in ideas that can be used to design innovative technologies and services that will appeal to consumers. As we've seen in recen...